Medoflucon Dosage/Direction for Use

"Medoflucon" capsules are for oral administration.
Daily dose of fluconazole should be based on the severity and nature of the fungal infection. For infections requiring multiple doses, treatment should continue until clinical and laboratory tests indicate the subsidence of active fungal infection. An inadequate period of treatment may lead to active infection reoccurring. In patients with cryptococcal meningitis and AIDS, maintenance therapy is usually required to prevent reoccurrence of infection.
Adults: Vaginal candidiasis, a single 150mg dose.
Oropharyngeal candidiasis, 50mg once a day for seven to fourteen days. Treatment should not normally exceed fourteen days except in severely immunocompromised patients.
Atrophic oral candidiasis, 50mg once a day for fourteen days.
Oesophagitis, non invasive bronchopulmonary infection, mucocutaneous candidiasis and candiduria, 50mg once daily for fourteen to thirty days.
The daily dose may be increased to 100mg for unusually difficult mucosal candidal infections.
Tinea pedis, tinea cruris, tinea corporis, tinea versicolor and dermal Candida infection, 50mg once a day for two to four weeks. Tinea pedis may require treatment for up to six weeks. Six week treatment duration should not normally be exceeded.
Candidaemia, disseminated candidiasis and invasive candidal infections, an initial dose of 400mg on the first day followed by 200mg once a day. If required by the clinical response, the dose may be increased to 400mg once a day. The length of treatment is dictated by clinical response.
Cryptococcal meningitis and other cryptococcal infections, an initial dose of 400mg on the first day followed by 200mg - 400mg once a day. The length of treatment depends on mycological and clinical response, for cryptococcal meningitis it is usually six to eight weeks. For prevention of relapse following primary therapy in patients with AIDS, indefinite administration of 100mg - 200mg once a day.
To prevent fungal infection in immunocompromised patients at risk due to neutropenia consequent upon cytotoxic chemotherapy or radiotherapy, 50mg to 400mg once a day. High risk patients, such as bone marrow transplants, should receive 400mg once a day. Dosage should be initiated several days before the anticipated onset of neutropenia and should be continued for seven days after neutrophil count has exceeded 1000 cells/mm³.
Children: Due to the dosage form, use in very young children is not recommended. Duration of therapy is based on clinical and mycological response.
Children over four weeks old: Mucosal candidiasis, 3mg/kg body weight once a day. A loading dose of 6mg/kg bodyweight may be given on the first day to rapidly achieve steady state.
Systemic candidiasis and cryptococcal infections, 6mg - 12mg/kg body weight once a day, depending upon the severity of the infection.
Prevention of fungal infection in immunocompromised patients at risk as a consequence of induced neutropenia, 3mg - 12mg/kg body weight depending upon the extent and duration of the neutropenia.
Children less than four weeks old: A capsule dosage form is not suitable for this age group.
Elderly: No dosage adjustment is necessary unless there is renal impairment (creatinine clearance <40ml/min).
Renal Impairment: No dosage adjustment is necessary for single dose therapy.
In multiple dose therapy, normal dose should be administered on day 1 and day 2. If creatinine clearance is between 21ml - 40ml/min, either subsequently give half the normal dose once a day or prolong the dosing interval to every two days. If creatinine clearance is 10ml - 20ml/min, either give one third the normal dose once a day or prolong the dosing interval to every three days.
Haemodialysis Patients: One dose after every haemodialysis session.